 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19827 News |  |
| «12...192193194195196197198199200201202203204» |
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice (clinicaltrials.gov) - Dec 23, 2012
P=N/A, N=550, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab (clinicaltrials.gov) - Dec 17, 2012
P2, N=88, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Combination therapy: CONCERTO: Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Dec 17, 2012
P3, N=395, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed
- || Humira (adalimumab) / AbbVie
Enrollment closed: Chronic Plaque Psoriasis (Ps) Registry (clinicaltrials.gov) - Dec 10, 2012
P=N/A, N=6000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. (clinicaltrials.gov) - Dec 6, 2012
P2, N=64, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab (clinicaltrials.gov) - Dec 6, 2012
P2, N=61, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Recruiting --> Completed
- New P4 trial: A randomised controlled trial to compare withdrawal of therapy versus continuing therapy in low disease states in psoriatic arthritis – feasibility study (EUDRACT) - Dec 3, 2012
P4, N=30, Ongoing, Sponsor: University of Leeds
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) (clinicaltrials.gov) - Nov 29, 2012
P2/3, N=40, Active, not recruiting, Sponsor: University of Heidelberg
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice (clinicaltrials.gov) - Nov 27, 2012
P=N/A, N=300, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- || Olumiant (baricitinib) / Incyte, Eli Lilly
New P3 trial, P3 data: A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis. (EUDRACT) - Nov 26, 2012
P3, N=1280, Ongoing, Sponsor: Eli Lilly and Company`Lilly S.A.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient (clinicaltrials.gov) - Nov 7, 2012
P3, N=80, Recruiting, Sponsor: Hamad Medical Corporation
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis (clinicaltrials.gov) - Nov 4, 2012
P4, N=106, Recruiting, Sponsor: Innovaderm Research Inc.
- |||||| Olumiant (baricitinib) / Incyte, Eli Lilly
Enrollment open: RA-BEAM: A Study in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Nov 1, 2012
P3, N=1280, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Humira (adalimumab) / AbbVie
Enrollment open: Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis (clinicaltrials.gov) - Oct 27, 2012
P3, N=200, Recruiting, Sponsor: Clalit Health Services
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial, Combination therapy: Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC) (clinicaltrials.gov) - Oct 25, 2012
P4, N=100, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate (clinicaltrials.gov) - Oct 25, 2012
P3, N=111, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||| Humira (adalimumab) / AbbVie
Enrollment open, HEOR: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (clinicaltrials.gov) - Oct 25, 2012
P3, N=455, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: HOPE 3: Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467)) (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=220, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting N=300 --> 220
- |||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Combination therapy: Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC) (clinicaltrials.gov) - Oct 24, 2012
P4, N=100, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
N=300 --> 220 Not yet recruiting --> Enrolling by invitation
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: HOPE 3: Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467)) (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=220, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment change: ADMIRE: A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (clinicaltrials.gov) - Oct 23, 2012
P4, N=33, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed N=50 --> 33
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: ADMIRE: A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (clinicaltrials.gov) - Oct 23, 2012
P4, N=33, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=50 --> 33 Active, not recruiting --> Completed
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial, PK/PD data: A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety (clinicaltrials.gov) - Oct 21, 2012
P2, N=100, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069 (clinicaltrials.gov) - Oct 18, 2012
P=N/A, N=125, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly
New P3 trial: RA-BEAM: A Study in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Oct 17, 2012
P3, N=1280, Recruiting, Sponsor: Eli Lilly and Company
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Oct 8, 2012
P2, N=10, Recruiting, Sponsor: Wayne State University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Oct 2, 2012
P2, N=10, Recruiting, Sponsor: Wayne State University
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial, Combination therapy: REACT2: Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy (clinicaltrials.gov) - Sep 30, 2012
P4, N=1200, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE) (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=547, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
New P3 trial: SPIRIT-P1: A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Sep 25, 2012
P3, N=412, Recruiting, Sponsor: Eli Lilly and Company
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR: Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=500, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: MAINTAIN: Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice (clinicaltrials.gov) - Sep 23, 2012
P4, N=780, Completed, Sponsor: Pfizer
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed N=2500 --> 4500
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=752, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=2500 --> 4500 Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab (clinicaltrials.gov) - Aug 29, 2012
P=N/A, N=500, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) (clinicaltrials.gov) - Aug 26, 2012
P3, N=54, Not yet recruiting, Sponsor: Peter Higgins
- ||||| Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: Long Term Open Label Continuation Study (clinicaltrials.gov) - Aug 23, 2012
P3, N=846, Completed, Sponsor: Abbott
Recruiting --> Active, not recruiting Initiation date: Feb 2000 --> Jul 2000
- ||| clazakizumab (CSL300) / CSL Behring
Enrollment closed, P2b data: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate (clinicaltrials.gov) - Aug 22, 2012
P2b, N=406, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Feb 2000 --> Jul 2000 Recruiting --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
New P3 trial, HEOR, Combination therapy: FOURIER: Adalimumab in the Treatment of Chronic Pouchitis (clinicaltrials.gov) - Aug 20, 2012
P3, N=24, Recruiting, Sponsor: Odense University Hospital
- Enrollment open: REDES-TNF: Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF (clinicaltrials.gov) - Aug 20, 2012
P4, N=190, Recruiting, Sponsor: Spanish Clinical Pharmacology Society
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Aug 16, 2012
P4, N=13, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=144 --> 13
- ||| Tremfya (guselkumab) / J&J
Enrollment closed: X-PLORE: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Aug 12, 2012
P2, N=293, Active, not recruiting, Sponsor: Janssen Inc.
N=144 --> 13 Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) (clinicaltrials.gov) - Aug 11, 2012
P=N/A, N=752, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=500 --> 752
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=566, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=500 --> 752 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Surveillance of Humira Injection in Korean Patients (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=1779, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Humira (adalimumab) / AbbVie
Trial withdrawal, HEOR: ELAN: Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=0, Withdrawn, Sponsor: Abbott
Enrolling by invitation --> Completed Not yet recruiting --> Withdrawn
- Humira (adalimumab) / AbbVie
Enrollment change, HEOR: ELAN: Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=0, Withdrawn, Sponsor: Abbott
Not yet recruiting --> Withdrawn N=2500 --> 0
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical: TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=60, Recruiting, Sponsor: University Hospital, Gentofte, Copenhagen
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: FA-Crohn: Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut (clinicaltrials.gov) - Jul 29, 2012
P1/2, N=25, Completed, Sponsor: University of Erlangen-Nürnberg Medical School
N=2500 --> 0 Recruiting --> Completed
- Humira (adalimumab) / AbbVie
Enrollment open: Vascular Inflammation in Psoriasis Trial (The VIP Trial) (clinicaltrials.gov) - Jul 26, 2012
P4, N=96, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Completed Not yet recruiting --> Recruiting